ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR

Non-Sponsored Content

ASCO 2018 HCC TRACK

SPOTLIGHT ON HEPATOCELLULAR CARCINOMA

By: Anne John Michael | Last updated: 10th June 2018 | In: ASCO 2018 Annual Meeting, Chemotherapy, Conferences, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Targeted Therapies, Translational Research

ASCO 2018 HCC Keywords

#ASCO18, apatinib, atezolizumab, Avastin, AXL, Bayer, bevacizumab, cabozantinib, CELESTIAL, cMET, Cometriq, Cyramza, doxorubicin, Eisai, Eli Lilly, Exelixis, Genentech, icaritin, Imclone, Keytruda, lenvatinib, Lenvima, Merck, MSD, Nexavar, PD-1, PD-L1, pembrolizumab, ramucirumab, REACH-2, Roche, SHR-1210, sorafenib, TACE, Tecentriq, TMB, VEGF, VEGFR

Hepatocellular carcinoma (HCC) is a rapidly deteriorating malignancy with poor prognosis. Since the introduction of sorafenib (SHARP and the Asia Pacific studies) a decade ago, successes with novel agents have been scarce. This year’s American Society of Clinical Oncology (ASCO) annual meeting included two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

NEW EVIDENCE FOR SECOND-LINE TARGETED THERAPIES IN ADVANCED HCC

In the randomised Phase III REACH-2 study (NCT02435433), ramucirumab significantly improved median overall survival (OS) (8.5 months) of patients with advanced HCC and elevated alpha-fetoprotein when compared to placebo (7.3 months) in the second-line treatment of HCC (P=0.0199).¹ The VEGFR2-directed monoclonal antibody (MAb) also significantly improved median progression-free survival (PFS) (2.8 months vs 1.6 months for placebo); P<0.0001), as well as increased the objective response rate (ORR) (4.6% vs 1.1% for placebo; P=0.1156) and disease control rate (DCR) (59.9% vs 38.9% for placebo; P=0.0006).¹

CELESTIAL (NCT01908426), another Phase III randomised trial in the second-line treatment of HCC, revealed that cabozantinib, a small molecule inhibitor of MET, the VEGF receptors, and AXL, significantly improved median OS (10.2 months vs 8.0 months for placebo; P=0.0049) and median PFS (5.2 months vs 1.9 months for placebo; P<0.0001) for previously treated patients with advanced HCC.² Subgroup analysis showed improved efficacy of cabozantinib, in both patients younger than 65 years as well as patients 65 years and older.³ Hepatitis B virus (HBV) was associated with HCC in patients younger than 65 years. The distribution of hepatitis C virus (HCV) was evenly distributed over the two age groups. Another subgroup analysis looked at CELESTIAL patients who received sorafenib as the only prior systemic therapy; cabozantinib improved the OS and PFS, an effect irrespective of the duration of sorafenib treatment.⁴

ADVANCES IN IMMUNOTHERAPY

The ASCO 2018 HCC track contained two studies that independently showed anti-tumour activity of pembrolizumab in the second-line for advanced liver cancer. Preliminary data from the open-label, Phase II KEYNOTE-224 trial (NCT02702414) indicated an ORR of 16.3% to pembrolizumab, an immunotherapy medication.⁵ The trial also revealed that at 12 months, pembrolizumab had a PFS rate of 25.4% and OS rate of 53.6%.⁵ Notably, in the KEYNOTE-224, 21% were HBV carrier and 26% were HCV carrier. Another Phase II trial showed a median time to tumour progression of 3 months and median OS of 14 months.⁶

Japanese investigators of the SCRUM-Japan GI-SCREEN study (UMIN000016343) looked at tumour mutation burden (TMB) in advanced gastrointestinal (GI) malignant tissue samples (N=1,759) in the Cancer Genome Atlas (TCGA) to determine which patients may confer benefit from immunotherapy.⁷ Twenty-seven (1.5%) HCC samples were included of which 7% were found to be TMB-high.⁷

Newsletter Sign-Up

Do you like our ASCO 2018 HCC coverage? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

ASCO 2021 Liver Cancer Update

Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

The evolving role of NK₁ in CINV management

Lung Cancer Update April 2021

11th June 2021

ASCO 2021 Liver Cancer Update

19th April 2021

Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients

ASCO2018 HCC ASCO18 hepatocellular carcinoma liver cancer keytruda pembrolizumab atezolizumab tecentriq cabozantinib levantinib ramucirumab REACH-2 CELESTIAL KEYNOTE-224

©MediPaper Medical Communications Ltd

Figure 1. Data of selected Phase II and III ASCO 2018 HCC studies

AFP=alpha-fetoprotein; BCLC=Barcelona Clinic Liver Cancer staging; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; EHS=extrahepatic spread; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; NR=not reported; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TTP=time to progression; VI=vascular invasion.

TACE: UPDATES ON COMBINATION THERAPY AND REAL-WORLD USE

The Barcelona Clinic Liver Cancer (BCLC) criteria consider intermediate stage (B) HCC patients with multinodular disease and preserved liver function and good performance status (ECOG PS 0) candidates for TACE.⁸ BCLC intermediate stage (C) patients are those with extrahepatic spread (EHS) or vascular invasion (VI) and have a reduction in performance status of (ECOG PS 1 or 2); they are considered candidates for systemic treatment.⁸

The prospective, observational OPTIMIS trial (NCT01933945) included 1650 patients with unresectable HCC planned for TACE.⁹ The study found that 32% (N=529) had BCLC stage C disease at study entry. Moreover, 7% (N=118) had EHS and 7% (N=123) had VI.⁹ In total, 39% of patients receiving TACE at study entry were ineligible for the procedure by international and regional treatment guidelines.⁹ Additionally, the trial found that the rate of disease progression increased with multiple TACE procedures.⁹ The majority of the patients (91%) who became TACE ineligible during the course of the study (N=507) were either not prescribed sorafenib or received it late.⁹

Another study by Professor Kudo and colleagues investigated the combination of transarterial chemoembolisation (TACE) and sorafenib for patients with unresectable HCC in the randomised, open-label TACTICS trial (NCT01217034).¹⁰ In total 156 patients with Child-Pugh score ≤7, ECOG performance status ≤1, no VI, no EHS, a maximum lesion size ≤10 cm and with ≤10 nodules were randomised to sorafenib plus conventional TACE (cTACE) vs cTACE alone. ).¹⁰ Kudo et al. reported a significantly increased median PFS (25.2 months) when compared to cTACE alone (13.5 months) (p=0.006), the number of OS events had not been reached and the median time to unTACEable progression (TTUP) was 26.7 months (sorafenib plus cTACE) vs 20.6 (cTACE).¹⁰ There were no unexpected toxicities.¹⁰

©MediPaper Medical Communications Ltd

Figure 2. Data of selected Phase I ASCO 2018 HCC studies

BCLC=Barcelona Clinic Liver Cancer staging; CR=complete response; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; ORR= objective response rate; PD-1=Programmed Death 1; pts=patients; TRAE=treatment-related adverse events.

ASCO 2018 HCC: IN THE PIPELINE

A single arm Phase II trial of icaritin, a highly selective oestrogen receptor a 36 (ERa36) modulator, in advanced HCC (N=70) found the drug to be safe (NCT01972672).¹¹ No Grade 3 or higher drug-related adverse events were reported.¹¹ Median OS was 254 days and disease control was achieved in 34.4% of patients.¹¹ The study included subgroup analysis: the presence of high PD-L1 expression, interleukin (IL)-6 advantage, or a neutrophil-lymphocyte ratio (NLR)-advantage all showed better OS outcomes.¹¹

A Phase Ib study of patients with unresectable or metastatic HCC who were naive to systemic treatment revealed that atezolizumab plus bevacizumab was well tolerated and had no new safety signals (NCT02715531).¹² The combination therapy was associated with a 62% confirmed response rate in the selected study population.¹²

Another Phase I study investigated the combination of SHR-1210, a fully human IgG4 monoclonal antibody against PD-1, and VEGFR2 inhibitor apatinib in patients with several advanced GI cancers, including HCC refractory to standard therapy (NCT02942329).¹³ The investigators concluded the novel combination therapy had a manageable toxicity profile and showed early signs of clinical activity. Fourteen patients with HBV-related HCC were treated at different dosing levels and evaluable. The ORR and DCR were 50.0% and 85.7%, respectively.¹³

Finally, initial results from a Phase Ib trial combining the multikinase inhibitor lenvatinib with PD-1 MAb pembrolizumab in patients (N=13) with BCLC stage B (not amenable for TACE) or C, Child-Pugh class A, and ECOG PS ≤ 1 unresectable HCC (NCT03006926).¹⁴ The study revealed good safety profile and potential anti-tumour activity; with 6 partial responses and 6 stable diseases, the disease control rate (DCR) was 93%. The response assessment of 1 patient could not be evaluated.¹⁴

UNSUCCESSFUL CLINICAL DRUG CANDIDATES

Some ASCO 2018 HCC studies were not successful.

A Phase IB study showed that enzalutamide was not efficacious for patients with either androgen receptor (AR)-positive or AR-negative HCC.¹⁵ The trial also investigated the combination of enzalutamide plus sorafenib, but this combination was limited by drug-drug interactions (NCT02642913).¹⁵

A Phase II trial in the second-line setting for advanced HCC found that sorafenib plus doxorubicin after first-line failure on sorafenib did improve OS but was not well-tolerated.¹⁶ The investigators do not recommend further investigations of the combination therapy (NCT01840592).¹⁶

REFERENCES

Zhu AX et al. J Clin Oncol 2018;36(suppl):Abstr 4003

Abou-Alfa GK et al. J Clin Oncol 2018;36(suppl):Abstr 4019

Rimassa L et al. J Clin Oncol 2018;36(suppl):Abstr 4090

Kelley RK et al. J Clin Oncol 2018;36(suppl):Abstr 4088

Zhu AX et al. J Clin Oncol 2018;36(suppl):Abstr 4020

Feun LG et al. J Clin Oncol 2018;36(suppl):Abstr 4086

Nakamura Y et al. J Clin Oncol 2018;36(suppl):Abstr 12094

Forner A et al. Lancet 2018;391(10127):1301–14

Peck-Radosavljevic M et al. J Clin Oncol 2018;36(suppl):Abstr 4018

Kudo M et al. J Clin Oncol 2018;36(suppl):Abstr 4017

Sun Y et al. J Clin Oncol 2018;36(suppl):Abstr 4077

Stein S et al. J Clin Oncol 2018;36(suppl):Abstr 4074

Xu JM et al. J Clin Oncol 2018;36(suppl):Abstr 4075

Ikeda M et al. J Clin Oncol 2018;36(suppl):Abstr 4076

Harding JJ et al. J Clin Oncol 2018;36(suppl):Abstr 4083

El Dika IH et al. J Clin Oncol 2018;36(suppl):Abstr 4080

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

Lorlatinib FDA approved for metastatic ALK-positive NSCLC

ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

Management of Immune-Mediated Hepatitis: a Case Report

PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R CLL or SLL

©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R follicular lymphoma

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

Early breast cancer treatment in China remains conservative

immuno-oncology I-O treatment for the irAE Rash

©MediPaper Medical Communications Ltd

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

Venetoclax FDA label updated to include Minimal Residual Disease negativity data

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

DRIVER connects cancer patients in China and the United States to the best care

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Pembrolizumab and atezolizumab USPIs updated by FDA

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

Lenvatinib FDA approved for 1st-line treatment of HCC

©Alex011973 / 123RF Stock Photo

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information. July 31, 2018.

FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

Ribociclib FDA label updated to include pre- and perimenopausal women

Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours

T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia

FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information. July 13, 2018

Filgrastim-aafi FDA approved as Filgrastim Biosimilar

Ribociclib FDA label updated to include pre- and perimenopausal women

Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer

EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy. More Information. June 19, 2018

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1

FDA approves venetoclax in 2nd-line for patients with CLL or SLL

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Trackbacks & Pingbacks

Ramucirumab FDA approved for hepatocellular carcinoma | MediPaper says:

23rd May 2019 at 11:58 AM

[…] FDA approval was based on data of the multinational, double-blind, placebo-controlled, multicentre REACH‑2 (NCT02435433) study that randomised 292 advanced HCC patients with AFP ≥400 ng/mL and disease […]

Log in to Reply
Ramucirumab FDA approved for hepatocellular carcinoma | MediNews Asia says:

23rd May 2019 at 11:50 AM

[…] FDA approval was based on data of the multinational, double-blind, placebo-controlled, multicentre REACH‑2 (NCT02435433) study that randomised 292 advanced HCC patients with AFP ≥400 ng/mL and disease […]

Log in to Reply
Cabozantinib FDA approved in HCC patients failing sorafenib says:

17th January 2019 at 10:35 AM

[…] randomised, double-blind, placebo-controlled, multicentre CELESTIAL trial randomised 707 HCC patients with Child-Pugh Class A liver impairment and previously treated […]

Log in to Reply
ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised says:

5th November 2018 at 1:03 PM

[…] the Phase III, open-label, randomised REFCLECT (NCT01761266) study showed non-inferiority for levantinib -a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT- when compared to […]

Log in to Reply
ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised says:

3rd November 2018 at 10:35 PM

[…] sorafenib treatment in patients with advanced HCC from the Phase III REACH (NCT01140347) and REACH-2 studies (NCT02435433).2Zhu AX, et al. Ann Oncol 2018;29(8):mdy282.006 Patients in the REACH-2 were […]

Log in to Reply

Want to join the discussion?
Feel free to contribute!

Non-Sponsored Content

Share this entry

SPOTLIGHT ON HEPATOCELLULAR CARCINOMA

ASCO 2018 HCC Keywords

NEW EVIDENCE FOR SECOND-LINE TARGETED THERAPIES IN ADVANCED HCC

ADVANCES IN IMMUNOTHERAPY

Newsletter Sign-Up

Newsletter

YOU MAY ALSO LIKE

TACE: UPDATES ON COMBINATION THERAPY AND REAL-WORLD USE

ASCO 2018 HCC: IN THE PIPELINE

UNSUCCESSFUL CLINICAL DRUG CANDIDATES

REFERENCES

Disclaimer

Share this entry

YOU MAY ALSO LIKE